^
Association details:
| Biomarker: | BRAF V600E |
|---|---|
| Cancer: | Melanoma |
| Drug: | Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) + XL888 (HSP90 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combined BRAF and HSP90 inhibition in patients with unresectable BRAF V600E mutant melanoma
Excerpt:
XL888 in combination with vemurafenib has clinical activity in patients with advanced BRAFV600-mutant melanoma....We observed objective responses to the vemurafenib-XL888 combination in 15 of 20 evaluable patients (ORR 75%; 95% CI 51%–91%) with three complete (15%) and 12 partial (60%) responses…
DOI:
10.1158/1078-0432.CCR-18-0565
